Riximyo® (rituximab for injection) is a biosimilar biologic drug (biosimilar) to Rituxan®.
Indications have been granted on the basis of similarity between Riximyo® and the reference biologic drug Rituxan®.
Non-Hodgkin’s Lymphoma (NHL):
Riximyo® (rituximab for injection) is indicated for:
the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin’s lymphoma.
the treatment of patients with CD20 positive, diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.
the treatment of patients with previously untreated Stage III/IV follicular, CD20 positive, B-cell non-Hodgkin's lymphoma in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy.
the maintenance treatment of patients with follicular non-Hodgkin’s lymphoma who have responded to induction therapy with either CHOP or CHOP plus rituximab.
single-agent maintenance treatment of previously untreated patients with advanced follicular non-Hodgkin’s lymphoma with high tumour burden and who have responded to induction therapy with either CHOP plus rituximab or CVP plus rituximab.
Chronic Lymphocytic Leukemia (CLL)
Riximyo® (rituximab for injection) is indicated for the treatment of patients with previously untreated or previously treated B-cell chronic lymphocytic leukemia (B-CLL), Binet Stage B or C, in combination with fludarabine and cyclophosphamide.
The use of Riximyo in CLL is based on an improvement in progression-free survival. Overall survival benefit has not been demonstrated in patients with previous treatment for CLL. The efficacy of treatment with R-FC (rituximab-fludarabine and cyclophosphamide) in CLL patients who were previously treated with rituximab in combination with fludarabine and cyclophosphamide has not been studied (see CLINICAL TRIALS for details).
Rheumatoid Arthritis (RA)
Riximyo® (rituximab for injection) in combination with methotrexate is indicated in adult patients:
to reduce signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tumour necrosis factor (TNF) inhibitor therapies.
Rituximab in combination with methotrexate has been shown to reduce the rate of progression of joint damage as measured by x-ray.
Riximyo® is the fourth Sandoz biosimilar available in Canada.
Click hereto consult the product monograph of Riximyo®.
* Riximyo® is a registered trademark owned or used under license by Sandoz Canada Inc.
** Rituxan® is a registered trademark of Roche in Canada.